News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
594,439 Results
Type
Article (47591)
Company Profile (121)
Press Release (546716)
Multimedia
Podcasts (154)
Webinars (22)
Section
Business (156763)
Career Advice (2455)
Deals (29298)
Drug Delivery (152)
Drug Development (71965)
Employer Resources (160)
FDA (16220)
Job Trends (12620)
News (281604)
Policy (30843)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2417)
Academic (1)
Accelerated approval (45)
Adcomms (37)
Allergies (156)
Alliances (37317)
ALS (189)
Alzheimer's disease (1821)
Antibody-drug conjugate (ADC) (378)
Approvals (16406)
Artificial intelligence (568)
Autoimmune disease (225)
Automation (40)
Bankruptcy (320)
Best Places to Work (9696)
BIOSECURE Act (23)
Biosimilars (203)
Biotechnology (72)
Bladder cancer (179)
Brain cancer (60)
Breast cancer (648)
Cancer (5128)
Cardiovascular disease (460)
Career advice (2081)
Career pathing (43)
CAR-T (275)
CDC (71)
Celiac Disease (1)
Cell therapy (787)
Cervical cancer (41)
Clinical research (62244)
Collaboration (1678)
Company closure (6)
Compensation (1271)
Complete response letters (90)
COVID-19 (2776)
CRISPR (96)
C-suite (916)
Cystic fibrosis (149)
Data (6742)
Decentralized trials (3)
Denatured (34)
Depression (170)
Dermatology (57)
Diabetes (539)
Diagnostics (5900)
Digital health (42)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (261)
Drug pricing (232)
Drug shortages (33)
Duchenne muscular dystrophy (277)
Earnings (70910)
Editorial (71)
Employer branding (20)
Employer resources (143)
Events (97922)
Executive appointments (959)
FDA (19606)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (26)
Funding (1426)
Gene editing (211)
Generative AI (51)
Gene therapy (681)
GLP-1 (1134)
Government (4482)
Grass and pollen (8)
Guidances (390)
Healthcare (15756)
HIV (75)
Huntington's disease (56)
IgA nephropathy (94)
Immunology and inflammation (317)
Immuno-oncology (85)
Indications (146)
Infectious disease (3079)
Inflammatory bowel disease (199)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (259)
Interviews (457)
IPO (14727)
IRA (58)
Job creations (3223)
Job search strategy (1698)
JPM (69)
Kidney cancer (19)
Labor market (91)
Layoffs (626)
Leadership (44)
Legal (7248)
Liver cancer (98)
Longevity (23)
Lung cancer (687)
Lymphoma (392)
Machine learning (49)
Management (53)
Manufacturing (856)
MASH (184)
Medical device (12055)
Medtech (12122)
Mergers & acquisitions (15652)
Metabolic disorders (1483)
mRNA (202)
Multiple sclerosis (162)
NASH (23)
Neurodegenerative disease (402)
Neuropsychiatric disorders (110)
Neuroscience (3214)
Neurotech (2)
NextGen: Class of 2026 (5247)
Non-profit (3443)
Now hiring (35)
Obesity (738)
Opinion (301)
Ovarian cancer (171)
Pain (217)
Pancreatic cancer (250)
Parkinson's disease (339)
Partnered (26)
Patents (531)
Patient recruitment (564)
Peanut (58)
People (46333)
Pharmaceutical (35)
Pharmacy benefit managers (34)
Phase 1 (18537)
Phase 2 (27064)
Phase 3 (21933)
Pipeline (6811)
Policy (360)
Postmarket research (2380)
Preclinical (7667)
Press Release (37)
Prostate cancer (280)
Psychedelics (59)
Radiopharmaceuticals (282)
Rare diseases (1050)
Real estate (4475)
Recruiting (65)
Regulatory (24131)
Reports (44)
Research institute (2189)
Resumes & cover letters (411)
Rett syndrome (32)
RNA editing (17)
RSV (81)
Schizophrenia (169)
Series A (243)
Series B (185)
Service/supplier (9)
Sickle cell disease (106)
Special edition (27)
Spinal muscular atrophy (151)
Sponsored (50)
Startups (2881)
State (1)
Stomach cancer (21)
Supply chain (117)
Tariffs (102)
The Weekly (118)
Vaccines (1154)
Venture capital (106)
Weight loss (517)
Women's health (93)
Worklife (23)
Date
Last 7 days (590)
Last 30 days (2392)
Last 365 days (28847)
2026 (7678)
2025 (29126)
2024 (32397)
2023 (36408)
2022 (46598)
2021 (50277)
2020 (47277)
2019 (38257)
2018 (28976)
2017 (28898)
2016 (27407)
2015 (30733)
2014 (24229)
2013 (19681)
2012 (21168)
2011 (21621)
2010 (19528)
Location
Africa (709)
Alabama (79)
Alaska (6)
Arizona (266)
Arkansas (11)
Asia (34024)
Australia (5953)
California (11619)
Canada (2831)
China (1062)
Colorado (466)
Connecticut (507)
Delaware (334)
Europe (82802)
Florida (1750)
Georgia (362)
Hawaii (4)
Idaho (43)
Illinois (858)
India (65)
Indiana (486)
Iowa (22)
Japan (467)
Kansas (109)
Kentucky (32)
Louisiana (30)
Maine (75)
Maryland (1409)
Massachusetts (8352)
Michigan (298)
Minnesota (616)
Mississippi (5)
Missouri (134)
Montana (13)
Nebraska (23)
Nevada (125)
New Hampshire (65)
New Jersey (3149)
New Mexico (17)
New York (3034)
North Carolina (1484)
North Dakota (7)
Northern California (5811)
Ohio (315)
Oklahoma (17)
Oregon (34)
Pennsylvania (2242)
Puerto Rico (21)
Rhode Island (34)
South America (1068)
South Carolina (73)
South Dakota (1)
Southern California (4576)
Tennessee (174)
Texas (1767)
United States (40660)
Utah (312)
Virginia (277)
Washington D.C. (75)
Washington State (923)
West Virginia (4)
Wisconsin (118)
Wyoming (1)
594,439 Results for "sigma tau finanziaria s p a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
J&J’s Anti-Tau Bet Falls Flat in Mid-Stage Alzheimer’s Trial
Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau antibody failed to slow clinical decline in patients with early Alzheimer’s disease.
November 24, 2025
·
1 min read
·
Heather McKenzie
Press Releases
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
March 20, 2026
·
6 min read
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
Press Releases
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
December 19, 2025
·
1 min read
Alzheimer’s disease
Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space
Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief Clinical Officer Lynn Kramer expressed unwavering conviction in his company’s own anti-tau asset, while others suggest the Alzheimer’s field is heading in a completely different direction.
December 5, 2025
·
4 min read
·
Heather McKenzie
Press Releases
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
March 9, 2026
·
12 min read
Press Releases
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
March 31, 2026
·
5 min read
Press Releases
C2N Diagnostics Highlights First Use of Its eMTBR-tau243 Plasma Assay in Evoke/Evoke+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic Alzheimer’s Disease
March 19, 2026
·
3 min read
Alzheimer’s disease
Sanofi’s Neuro Push Arrives in Seoul With $1B+ Alzheimer’s Play
The star of the agreement targets a specific type of tau protein, helping to prevent toxic accumulation in the brain while also preserving the function of healthy tau.
December 16, 2025
·
1 min read
·
Tristan Manalac
Press Releases
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
February 25, 2026
·
7 min read
1 of 59,444
Next
